phrykt

Monte Rosa Therapeutics, Inc. (GLUE): who owns it and who trades it

As of Nov 16, 2026, GLUE insiders reported 35 open-market sales worth $4M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Filip Janku (Chief Medical Officer), with $1.3M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Monte Rosa Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns GLUE

194 funds and institutions reported GLUE shares worth $2.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is T. Rowe Price Associates with 11.1%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

T. Rowe Price Associates11.1%
NEA Management Company, LLC9.6%
BlackRock, Inc.8.6%
TCG Crossover Management, LLC5.8%
Vestal Point Capital, LP5.7%
Bvf Inc5.6%
Baker Bros. Advisors LP5.4%
State Street Corp4.7%
Montanova Capital, LLC4.4%
Vanguard Capital Management LLC4.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
T. Rowe Price Associates8.86M11.07%$214M+32%
NEA Management Company, LLC7.69M9.61%$186MNo change
BlackRock, Inc.6.84M8.55%$166M+21%
TCG Crossover Management, LLC4.62M5.78%$112MNo change
Vestal Point Capital, LP4.60M5.75%$111M+28%
Bvf Inc4.46M5.58%$108MNo change
Baker Bros. Advisors LP4.35M5.43%$105MNo change
State Street Corp3.73M4.66%$90.3M+11%
Montanova Capital, LLC3.55M4.44%$85.9M-16%
Vanguard Capital Management LLC3.41M4.27%$82.6M+10%
Versant Venture Management, LLC3.18M3.98%$77MNo change
Braidwell LP2.45M3.06%$59.3M-24%
Geode Capital Management, LLC1.86M2.33%$45.1M+21%
American Century Companies Inc1.62M2.03%$39.3M-42%
Marshall Wace, LLP1.59M1.99%$38.6M+11%
Aisling Capital Management LP1.56M1.94%$37.6MNo change
California State Teachers Retirement System1.31M1.64%$54.2M–
Nantahala Capital Management, LLC1.30M1.63%$31.6M+100%
Bellevue Group AG1.19M1.49%$28.8M-5%
Dimensional Fund Advisors LP1.18M1.47%$28.5M+13%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, GLUE insiders reported $0 of open-market purchases and $4M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$4M
35 trades, 8 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Oct 5, 2026
Filed Oct 6, 2026

Purchases and sales by month

$1.7M$1.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 5, 2026Matthew BowenPrincipal Accounting OffSale13$10.56$137Form 4
Jul 16, 2026Markus WarmuthCEOSale9,500$23.18$220KForm 4
Jul 15, 2026Jennifer ChampouxChief Operating OfficerSale4,351$23.38$102KForm 4
Jul 6, 2026Sharon TownsonChief Scientific OfficerSale400$24.13$9.7KForm 4
Jul 6, 2026Sharon TownsonChief Scientific OfficerSale5,600$23.25$130KForm 4
Jun 30, 2026Filip JankuChief Medical OfficerSale5,407$24.50$132KForm 4
Jun 29, 2026Filip JankuChief Medical OfficerSale6,000$22.95$138KForm 4
Jun 29, 2026Anthony M. ManningDirectorSale10,000$23.11$231KForm 4
Jun 24, 2026Filip JankuChief Medical OfficerSale30,000$21.42$643KForm 4
Jun 23, 2026Filip JankuChief Medical OfficerSale11,845$20.22$240KForm 4
Jun 23, 2026Sharon TownsonChief Scientific OfficerSale3,000$20.00$60KForm 4
Jun 23, 2026Jennifer ChampouxChief Operating OfficerSale2,175$20.00$43.5KForm 4
Jun 17, 2026Jennifer ChampouxChief Operating OfficerSale2,176$19.00$41.3KForm 4
Jun 17, 2026Sharon TownsonChief Scientific OfficerSale3,000$19.00$57KForm 4
Jun 1, 2026Markus WarmuthCEOSale4,998$19.41$97KForm 4
Jun 1, 2026Markus WarmuthCEOSale468$19.73$9.2KForm 4
May 29, 2026Sharon TownsonChief Scientific OfficerSale6,000$19.87$119KForm 4
May 27, 2026Jennifer ChampouxChief Operating OfficerSale2,175$20.00$43.5KForm 4
May 22, 2026Jennifer ChampouxChief Operating OfficerSale2,176$19.00$41.3KForm 4
May 21, 2026Anthony M. ManningDirectorSale10,000$18.01$180KForm 4
May 1, 2026Markus WarmuthCEOSale5,467$18.92$103KForm 4
Apr 14, 2026Markus WarmuthCEOSale8,000$17.64$141KForm 4
Apr 9, 2026Philip NicksonChief Business & Legal OSale5,845$17.69$103KForm 4
Mar 4, 2026Edmund DunnPrincipal Accounting OffSale139$17.96$2.5KForm 4
Mar 2, 2026Markus WarmuthCEOSale5,466$17.92$98KForm 4
Mar 2, 2026Edmund DunnPrincipal Accounting OffSale536$17.50$9.4KForm 4
Feb 27, 2026Edmund DunnPrincipal Accounting OffSale25,164$18.10$455KForm 4
Feb 23, 2026Filip JankuChief Medical OfficerSale9,189$19.50$179KForm 4
Jan 7, 2026Markus WarmuthCEOSale309$24.57$7.6KForm 4
Jan 7, 2026Markus WarmuthCEOSale1,450$23.88$34.6KForm 4
Jan 7, 2026Markus WarmuthCEOSale3,707$23.24$86.2KForm 4
Jan 5, 2026Philip NicksonChief Business & Legal OSale3,155$15.17$47.9KForm 4
Jan 5, 2026Jennifer ChampouxChief Operating OfficerSale2,629$15.17$39.9KForm 4
Jan 5, 2026Edmund DunnPrincipal Accounting OffSale1,039$15.17$15.8KForm 4
Jan 5, 2026Markus WarmuthCEOSale10,135$15.17$154KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Filip JankuChief Medical Officer–$1.3MJun 30, 2026
Markus WarmuthPresident & CEO, Director–$951KJul 16, 2026
Edmund DunnPrincipal Accounting Officer–$483KMar 4, 2026
Anthony M. ManningDirector–$411KJun 29, 2026
Sharon TownsonChief Scientific Officer–$376KJul 6, 2026
Jennifer ChampouxChief Operating Officer–$311KJul 15, 2026
Philip NicksonChief Business & Legal Officer–$151KApr 9, 2026
Matthew BowenPrincipal Accounting Officer–$137Oct 5, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

GLUE short interest

Very high short interest. 24.4% of GLUE shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 39%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 20.86M GLUE shares were sold short, 24.4% of the shares outstanding, up 0.9% from the report before. At the average daily volume of 1.33M shares, buying them all back would take about 15.7 trading days (days to cover).

Shares short, % of all shares

24.4%May 15Oct 3025.3%

Days to cover

15.7May 15Oct 3022.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202620.86M24.41%+1%1.33M15.7
Oct 15, 202620.66M24.22%+5%1.84M11.2
Sep 30, 202619.69M23.08%+2%1.09M18.0
Sep 15, 202619.27M22.58%+7%1.13M17.1
Aug 31, 202618.08M21.19%+4%1.09M16.6
Aug 14, 202617.46M20.46%+6%1.25M14.0
Jul 31, 202616.46M19.29%-4%1.55M10.6
Jul 15, 202617.20M21.49%-8%1.31M13.1
Jun 30, 202618.63M23.29%+9%2.20M8.5
Jun 15, 202617.17M21.46%+7%1.03M16.6
May 29, 202616.01M20.00%+7%832,95319.2
May 15, 202614.96M18.70%-1%725,33420.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Monte Rosa Therapeutics company events

Monte Rosa Therapeutics filed 12 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 1, 2026AnnouncementThe Company announced positive data from GFORCE-1, a Phase 1 study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of NLRP3/IL-1-driven inflammatory diseases. Filing
  3. Sep 8, 2026AnnouncementAs previously disclosed, the Company is party to a global exclusive development and commercialization license agreement with Novartis pursuant to which Novartis has exclusive worldwide rights to develop, manufacture and commercialize VAV1-directed MGDs, including MRT-6160 (DDY391). Filing
  4. Aug 6, 2026ResultsReleased financial results. Filing
  5. Jun 11, 2026VoteReported shareholder vote results. Filing
  6. May 7, 2026ResultsReleased financial results. Filing
  7. Mar 17, 2026ResultsReleased financial results. Filing
  8. Feb 10, 2026LeadershipEdmund Dunn informed us of his intent to retire from the role of SVP, Corporate Controller and Principal Accounting Officer of Monte Rosa Therapeutics, Inc., effective as of April 3, 2026. Filing
  9. Jan 9, 2026AgreementMonte Rosa Therapeutics, Inc. entered into an Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters listed on Schedule 1 thereto, related to an underwritten public offering of 11,125,000 shares of the Company’s… Filing
  10. Jan 7, 2026AnnouncementMonte Rosa Therapeutics, Inc. terminated the sales agreement prospectus filed with the Company’s registration statement on Form S-3 (File No. 333-285942) and related to the shares of the Company’s common stock, par value $0.0001 per share, issuable pursuant to the Open Market Sale Agreement, dated… Filing
  11. Jan 7, 2026AnnouncementThe Company announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6. Filing
  12. Dec 16, 2025AnnouncementThe Company announced positive interim data from its ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic CRPC. The Phase 1/2 study evaluated 0.5 mg and 0.75 mg of MRT-2359 administered orally on a 21-days-on… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Monte Rosa Therapeutics financials

Famous investors that hold GLUE

5 of the 50 well-known investors we track reported holding GLUE in their latest 13F filing. The largest position is Ken Griffin's, worth $10.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026857,107$10.2M0.0%+424%
Steve Cohen · Point72 Asset ManagementQ3 2026770,673$9.2M0.0%New
Ken Fisher · Fisher Asset ManagementQ3 2026295,844$3.5M0.0%-19%
Israel Englander · Millennium ManagementQ3 2026161,037$1.9M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202642,597$508K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named GLUE in the last 120 days.

FiledHolderFormStake
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A2.6%
Nov 16, 2026T. Rowe Price Associates, Inc.13G/A8.6%
Nov 16, 2026Vestal Point Capital, LP13G/A8.4%
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A2.6%
Nov 16, 2026TCG Crossover GP II, LLC13G/A2.2%
Nov 16, 2026T. Rowe Price Associates, Inc.13G/A8.6%
Nov 16, 2026TCG Crossover GP II, LLC13G/A2.2%
Nov 16, 2026Vestal Point Capital, LP13G/A8.4%

Questions about Monte Rosa Therapeutics, Inc. (GLUE) stock

Who owns the most GLUE stock?

The largest reported owner of Monte Rosa Therapeutics, Inc. (GLUE) is T. Rowe Price Associates, with 11.1% of the company. In total, 194 funds and institutions reported holding GLUE at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are GLUE insiders buying or selling?

In the last 12 months, GLUE insiders reported no open-market purchases and 35 sales worth $4M. The latest trade was on Oct 5, 2026. See every trade.

What is the short interest in GLUE?

As of Oct 30, 2026, 20.86M GLUE shares were sold short, 24.4% of the shares outstanding, up 0.9% from the report before. At the average daily volume of 1.33M shares, buying them all back would take about 15.7 trading days (days to cover). See the history.

Which famous investors hold GLUE?

5 of the 50 well-known investors we track reported GLUE in their latest 13F filing, including Ken Griffin, Steve Cohen, Ken Fisher. The largest position is worth $10.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.